Flindokalner

DB16908InvestigationalSmall molecule

Flindokalner: Overview.

Mechanism: Pharmacologically active on Calcium-activated potassium channel subunit alpha-1, Potassium voltage-gated channel subfamily KQT member 2, and Potassium voltage-gated channel subfamily KQT member 4
Curator reviewed
Formula / weight: C₁₆H₁₀ClF₄NO₂ · 359.7 g/mol (avg)
Also known as: (3s)-(+)-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-(trifluoromethyl)-2h-indol-2-one · (3s)-3-(5-chloro-2-methoxyphenyl)-3-fluoro-6-(trifluoromethyl)-1,3-dihydro-2h-indol-2-one · 2h-indol-2-one, 3-(5-chloro-2-methoxyphenyl)-3-fluoro-1,3-dihydro-6-(trifluoromethyl)-, (3s)- · Maxipost
Code names: BMS-204352 · BMS-204352-01

Resolves to

Compound

Structure

InChIKeyULYONBAOIMCNEH-HNNXBMFYSA-NSMILESCOC1=CC=C(Cl)C=C1[C@]1(F)C(=O)NC2=C1C=CC(=C2)C(F)(F)F

Targets

What you can answer from here — as of June 15, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

11+ReferencesStructured and connected to the statements they support

Which drugs share a target with Flindokalner, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.